ISS pans Elan plans; Elan secures Royalty ban
This article was originally published in Scrip
Executive Summary
Elan has obtained injunctions in the US and Ireland against hostile bidder Royalty Pharma, blocking it from consummating its tender offer or sending its proxy statement to Elan shareholders. The Irish firm's complaint is that Royalty has failed to disclose information, such as the identity of its investors and details of what Royalty plans to do with Elan should it acquire a majority, which is required under Irish and US law.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.